ANCA-associated vasculitis following ChAdOx1 nCoV19 vaccination: case-based review
Abstract For the foreseeable future, vaccines are the cornerstone in the global campaign against the Coronavirus Disease-19 (COVID-19) pandemic. As the number and fatalities due to COVID-19 decline and the lockdown anywise rescinded, we recognize an increase in the incidence of autoimmune disease post-COVID-19 vaccination. However, the causality of the most vaccine-induced side effects is debatable and, at best, limited to a temporal correlation. We herein report a case of a 51-year-old gentleman who developed Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis (AAV) 2 week post-COVID-19 vaccination. The patient responded favorably to oral steroids and rituximab. Additionally, we conducted a case-based review of vaccine-associated AAV describing their clinical manifestations and treatment response of this emerging entity..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Rheumatology international - 42(2022), 4 vom: 05. Feb., Seite 749-758 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Prabhahar, Arun [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
ANCA-associated vasculitis |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022 |
|---|
| doi: |
10.1007/s00296-021-05069-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2078313750 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2078313750 | ||
| 003 | DE-627 | ||
| 005 | 20230509190701.0 | ||
| 007 | tu | ||
| 008 | 221220s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00296-021-05069-x |2 doi | |
| 035 | |a (DE-627)OLC2078313750 | ||
| 035 | |a (DE-He213)s00296-021-05069-x-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Prabhahar, Arun |e verfasserin |0 (orcid)0000-0001-8722-6413 |4 aut | |
| 245 | 1 | 0 | |a ANCA-associated vasculitis following ChAdOx1 nCoV19 vaccination: case-based review |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022 | ||
| 520 | |a Abstract For the foreseeable future, vaccines are the cornerstone in the global campaign against the Coronavirus Disease-19 (COVID-19) pandemic. As the number and fatalities due to COVID-19 decline and the lockdown anywise rescinded, we recognize an increase in the incidence of autoimmune disease post-COVID-19 vaccination. However, the causality of the most vaccine-induced side effects is debatable and, at best, limited to a temporal correlation. We herein report a case of a 51-year-old gentleman who developed Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis (AAV) 2 week post-COVID-19 vaccination. The patient responded favorably to oral steroids and rituximab. Additionally, we conducted a case-based review of vaccine-associated AAV describing their clinical manifestations and treatment response of this emerging entity. | ||
| 650 | 4 | |a COVID-19 vaccine | |
| 650 | 4 | |a SARS-CoV-2 vaccine | |
| 650 | 4 | |a ANCA-associated vasculitis | |
| 650 | 4 | |a Auto-immunity | |
| 650 | 4 | |a Glomerulonephritis | |
| 700 | 1 | |a Naidu, G. S. R. S. N. K. |0 (orcid)0000-0002-9727-044X |4 aut | |
| 700 | 1 | |a Chauhan, Prabhat |0 (orcid)0000-0001-5876-9232 |4 aut | |
| 700 | 1 | |a Sekar, Aravind |0 (orcid)0000-0003-0196-3442 |4 aut | |
| 700 | 1 | |a Sharma, Aman |0 (orcid)0000-0003-0813-1243 |4 aut | |
| 700 | 1 | |a Sharma, Alok |4 aut | |
| 700 | 1 | |a Kumar, Asheesh |4 aut | |
| 700 | 1 | |a Nada, Ritambhra |0 (orcid)0000-0002-8955-1428 |4 aut | |
| 700 | 1 | |a Rathi, Manish |0 (orcid)0000-0002-2642-8895 |4 aut | |
| 700 | 1 | |a Kohli, Harbir Singh |0 (orcid)0000-0003-4806-2297 |4 aut | |
| 700 | 1 | |a Ramachandran, Raja |0 (orcid)0000-0002-1273-9107 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology international |d Springer Berlin Heidelberg, 1981 |g 42(2022), 4 vom: 05. Feb., Seite 749-758 |w (DE-627)129098183 |w (DE-600)8286-7 |w (DE-576)014434903 |x 0172-8172 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2022 |g number:4 |g day:05 |g month:02 |g pages:749-758 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s00296-021-05069-x |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2022 |e 4 |b 05 |c 02 |h 749-758 | ||